Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Richard Young
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Syros Pharmaceuticals
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Young is a founder, member of the Board of Directors and consultant to Syros Pharmaceuticals. (The "payment for services" reported above includes compensation for consulting and Board service.) The interests of the company overlap with the research subject matter of the funded awards referenced above. A management plan is required to assure that Dr. Young's relationship with the companies will not influence the integrity of the research.
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
The potent oncogene MYCN is amplified in half of high-risk neuroblastoma cases, but devising strategies to inhibit this transcription factor has been challenging. We propose to take advantage of recent findings that oncogenic MYC upregulates the active transcriptional program in cancer cells and is transcriptionally regulated by large enhancer regions that facilitate its high-level expression and that are especially sensitive to perturbation. By using a novel covalent inhibitor of CDK7, a kinase that has crucial roles in gene transcription and cell cycle regulation, we will explore the potential of targeting MYCN-induced transcription as a novel therapeutic strategy for patients with MYCN-amplified neuroblastoma.
Filed on December 11, 2017.
Tell us what you know about Richard Young's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Richard Young”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | $100,000 - $149,999 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | $100,000 - $149,999 |
| Richard Young | Massachusetts Institute of Technology | Conflict of Interest | Syros Pharmaceuticals | Value cannot be readily determined |
| Richard Young | Dana Farber Cancer Inst | Conflict of Interest | Syros Pharmaceuticals | >$600,000 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Omega Therapeutics | $20,000 - $39,999 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | $100,000 - $149,999 |
| Richard Young | Dana Farber Cancer Inst | Conflict of Interest | Syros Pharmaceuticals | >$600,000 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | Value cannot be readily determined |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Marauder Therapeutics, Inc. | $100,000 - $149,999 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.